Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

455
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
455
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

387
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
387
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

326
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
326
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

490
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
490
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.3K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.3K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

439
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
439

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epicardial Fat Drives Macrophage Response in Atrial Cardiomyopathy.

Circulation research·2026
Same author

Towards new animal models of pure hypoxic Lance-Adams syndrome: Negative results.

PloS one·2026
Same author

Fibrotic-like collagen matrices as 3D <i>in vitro</i> models for investigating the impact of pathological extracellular matrix on skeletal muscle cell behavior.

Biomaterials science·2026
Same author

CAR-T cells targeting fibroblast activation protein eliminate pathological fibroblasts and preserve cardiac function in a Duchenne Muscular Dystrophy murine model.

Stem cell research & therapy·2026
Same author

Simtuzumab Attenuates Loxl2-Mediated Extracellular Matrix Remodeling and Preserves Cardiac Function in <i>LMNA</i> Mutation-Induced Dilated Cardiomyopathy.

Circulation. Heart failure·2026
Same author

Desmin mutations in cardiomyocytes increase susceptibility to coxsackievirus B3 infection by impairing antiviral IFN-β response and upregulating viral receptors expression.

Stem cell research & therapy·2026

Related Experiment Video

Updated: Jan 12, 2026

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
08:13

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

6.4K

Exploring Desmin as a Potential Modifier in Duchenne Muscular Dystrophy-Associated Cardiomyopathy.

Brice-Emmanuel Guennec1, Yeranuhi Hovhannisyan1, Gaëlle Revet1

  • 1Institut de Biologie Paris-Seine (IBPS), UMR CNRS 8263, INSERM U1345, Development, Adaptation and Ageing, Sorbonne Université, Paris, France.

Acta Physiologica (Oxford, England)
|October 30, 2025
PubMed
Summary

Increased filamentous desmin appears protective in Duchenne muscular dystrophy (DMD) mouse models, suggesting desmin as a potential therapeutic target for DMD cardiomyopathy.

Keywords:
Duchenne muscular dystrophycardiomyopathydesmin intermediate filamentdisease‐modifier proteinsmdx mice

More Related Videos

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.5K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.3K

Related Experiment Videos

Last Updated: Jan 12, 2026

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
08:13

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

6.4K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.5K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.3K

Area of Science:

  • Muscle physiology
  • Genetic disorders
  • Cardiovascular research

Background:

  • Duchenne muscular dystrophy (DMD) is a severe X-linked genetic disorder causing progressive muscle degeneration due to dystrophin loss.
  • Modifier proteins, like desmin, may influence DMD progression and associated cardiomyopathy.
  • Desmin is elevated in skeletal muscle of mdx mice, a mild DMD model.

Purpose of the Study:

  • To investigate the role of desmin as a modifier protein in Duchenne muscular dystrophy-associated cardiomyopathy.
  • To determine if altered desmin levels impact disease severity in DMD models.

Main Methods:

  • Quantified soluble and insoluble desmin in hearts of mdx mice and GRMD dogs.
  • Assessed desmin-regulatory proteins in mdx mice.
  • Generated desmin-deficient (mdx-Des-/-) and partially deficient (mdx-Des+/-) mdx mice for phenotypic analysis, including cardiac function and histology.

Main Results:

  • In mdx mice, insoluble, phosphorylated desmin increased; GRMD dogs showed no increase.
  • Desmin deficiency aggravated dystrophic features, cardiac dysfunction, and fibrosis in mdx mice.
  • Partial desmin reduction abrogated insoluble desmin increase and worsened the mdx phenotype.

Conclusions:

  • Elevated filamentous desmin exhibits a protective effect in mdx mouse hearts, modulating DMD cardiomyopathy severity.
  • Desmin acts as a modifier in DMD, indicating its potential as a therapeutic target for DMD cardiomyopathy.